Literature DB >> 32195001

The identification of a CD47-blocking "hotspot" and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination.

Rui Shi1,2, Yan Chai3, Jianhua Zhu4, Jinghua Yan1,2,3,5, Xiaomin Duan1,2, Xiaoshan Bi1,5, Qingrui Huang1, Qihui Wang1, Shuguang Tan3, George F Gao2,3.   

Abstract

Keywords:  Drug development; Structural biology

Year:  2020        PMID： 32195001      PMCID： PMC7058617          DOI： 10.1038/s41392-020-0121-2

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN： 2059-3635


× No keyword cloud information.
  9 in total

1.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors:  Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Authors:  Stephen B Willingham; Jens-Peter Volkmer; Andrew J Gentles; Debashis Sahoo; Piero Dalerba; Siddhartha S Mitra; Jian Wang; Humberto Contreras-Trujillo; Robin Martin; Justin D Cohen; Patricia Lovelace; Ferenc A Scheeren; Mark P Chao; Kipp Weiskopf; Chad Tang; Anne Kathrin Volkmer; Tejaswitha J Naik; Theresa A Storm; Adriane R Mosley; Badreddin Edris; Seraina M Schmid; Chris K Sun; Mei-Sze Chua; Oihana Murillo; Pradeep Rajendran; Adriel C Cha; Robert K Chin; Dongkyoon Kim; Maddalena Adorno; Tal Raveh; Diane Tseng; Siddhartha Jaiswal; Per Øyvind Enger; Gary K Steinberg; Gordon Li; Samuel K So; Ravindra Majeti; Griffith R Harsh; Matt van de Rijn; Nelson N H Teng; John B Sunwoo; Ash A Alizadeh; Michael F Clarke; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

3.  A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells.

Authors:  Emily C Piccione; Silvia Juarez; Jie Liu; Serena Tseng; Christine E Ryan; Cyndhavi Narayanan; Lijuan Wang; Kipp Weiskopf; Ravindra Majeti
Journal:  MAbs       Date:  2015       Impact factor: 5.857

4.  CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

Authors:  Ravindra Majeti; Mark P Chao; Ash A Alizadeh; Wendy W Pang; Siddhartha Jaiswal; Kenneth D Gibbs; Nico van Rooijen; Irving L Weissman
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

5.  Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47.

Authors:  Deborah Hatherley; Stephen C Graham; Jessie Turner; Karl Harlos; David I Stuart; A Neil Barclay
Journal:  Mol Cell       Date:  2008-07-25       Impact factor: 17.970

6.  Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

Authors:  Leora Horn; David R Spigel; Everett E Vokes; Esther Holgado; Neal Ready; Martin Steins; Elena Poddubskaya; Hossein Borghaei; Enriqueta Felip; Luis Paz-Ares; Adam Pluzanski; Karen L Reckamp; Marco A Burgio; Martin Kohlhäeufl; David Waterhouse; Fabrice Barlesi; Scott Antonia; Oscar Arrieta; Jérôme Fayette; Lucio Crinò; Naiyer Rizvi; Martin Reck; Matthew D Hellmann; William J Geese; Ang Li; Anne Blackwood-Chirchir; Diane Healey; Julie Brahmer; Wilfried E E Eberhardt
Journal:  J Clin Oncol       Date:  2017-10-12       Impact factor: 44.544

7.  CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.

Authors:  Ranjana Advani; Ian Flinn; Leslie Popplewell; Andres Forero; Nancy L Bartlett; Nilanjan Ghosh; Justin Kline; Mark Roschewski; Ann LaCasce; Graham P Collins; Thu Tran; Judith Lynn; James Y Chen; Jens-Peter Volkmer; Balaji Agoram; Jie Huang; Ravindra Majeti; Irving L Weissman; Chris H Takimoto; Mark P Chao; Sonali M Smith
Journal:  N Engl J Med       Date:  2018-11-01       Impact factor: 91.245

Review 8.  Macrophages are critical effectors of antibody therapies for cancer.

Authors:  Kipp Weiskopf; Irving L Weissman
Journal:  MAbs       Date:  2015       Impact factor: 5.857

9.  CD47 blockade triggers T cell-mediated destruction of immunogenic tumors.

Authors:  Xiaojuan Liu; Yang Pu; Kyle Cron; Liufu Deng; Justin Kline; William A Frazier; Hairong Xu; Hua Peng; Yang-Xin Fu; Meng Michelle Xu
Journal:  Nat Med       Date:  2015-08-31       Impact factor: 53.440
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.